Metagenomi, Inc. Common Stock (MGX) - Net Assets
Based on the latest financial reports, Metagenomi, Inc. Common Stock (MGX) has net assets worth $137.78 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($196.95 Million) and total liabilities ($59.17 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Metagenomi, Inc. Common Stock (MGX) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $137.78 Million |
| % of Total Assets | 69.96% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 20.81 |
Metagenomi, Inc. Common Stock - Net Assets Trend (2021–2025)
This chart illustrates how Metagenomi, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. See Metagenomi, Inc. Common Stock defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Metagenomi, Inc. Common Stock (2021–2025)
The table below shows the annual net assets of Metagenomi, Inc. Common Stock from 2021 to 2025. For live valuation and market cap data, see MGX market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | $158.60 Million | -32.47% |
| 2024-09-30 | $234.86 Million | +9.15% |
| 2023-09-30 | $215.17 Million | +389.10% |
| 2022-09-30 | $-74.43 Million | -128.70% |
| 2021-09-30 | $-32.54 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Metagenomi, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 27777400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.00K | 0.00% |
| Other Comprehensive Income | $260.00K | 0.16% |
| Other Components | $469.20 Million | 295.85% |
| Total Equity | $158.60 Million | 100.00% |
Metagenomi, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Metagenomi, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Moorim Paper
KO:009200
|
$44.44 Million |
|
GenMont Biotech Inc
TW:3164
|
$44.44 Million |
|
Liberty Shoes Limited
NSE:LIBERTSHOE
|
$44.46 Million |
|
Investment and Trading of Real Estate JSC
VN:ITC
|
$44.47 Million |
|
MBL Infrastructure Limited
NSE:MBLINFRA
|
$44.42 Million |
|
Leading Edge Materials Corp
V:LEM
|
$44.40 Million |
|
EPE Capital Partners Ltd
JSE:EPE
|
$44.40 Million |
|
PASSUS S.A. ZY-1
F:71X
|
$44.40 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Metagenomi, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 234,857,000 to 158,596,000, a change of -76,261,000 (-32.5%).
- Net loss of 87,868,000 reduced equity.
- Other comprehensive income decreased equity by 449,000.
- Other factors increased equity by 12,056,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-87.87 Million | -55.4% |
| Other Comprehensive Income | $-449.00K | -0.28% |
| Other Changes | $12.06 Million | +7.6% |
| Total Change | $- | -32.47% |
Book Value vs Market Value Analysis
This analysis compares Metagenomi, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.28x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-09-30 | $-5.49 | $1.18 | x |
| 2022-09-30 | $-1.99 | $1.18 | x |
| 2023-09-30 | $5.74 | $1.18 | x |
| 2024-09-30 | $6.28 | $1.18 | x |
| 2025-09-30 | $4.26 | $1.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Metagenomi, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -55.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -348.54%
- • Asset Turnover: 0.11x
- • Equity Multiplier: 1.39x
- Recent ROE (-55.40%) is below the historical average (-24.07%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | -8823.87% | 0.00x | 0.00x | $-18.19 Million |
| 2022 | 0.00% | -253.45% | 0.04x | 0.00x | $-36.15 Million |
| 2023 | -31.72% | -152.50% | 0.12x | 1.70x | $-89.77 Million |
| 2024 | -33.24% | -149.26% | 0.16x | 1.38x | $-101.54 Million |
| 2025 | -55.40% | -348.54% | 0.11x | 1.39x | $-103.73 Million |
Industry Comparison
This section compares Metagenomi, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Metagenomi, Inc. Common Stock (MGX) | $137.78 Million | 0.00% | 0.43x | $44.42 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Metagenomi, Inc. Common Stock
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for … Read more